文献速递造血干细胞移植与细胞治疗

造血干细胞移植治疗嘌呤核苷磷酸化酶缺乏症:一项EBMT-IEWP回顾性研究

Hematopoietic stem cell transplantation for purine nucleoside phosphorylase deficiency: an EBMT-IEWP retrospective study.
PubMed 文献 · Blood · 2026-01-01

这项EBMT-IEWP回顾性研究纳入21个中心的46例嘌呤核苷磷酸化酶缺乏症患者,分析移植前表现及造血干细胞移植后结局。中位随访7.9年,40例存活,3年总生存率86%、无事件生存率75%;初次表现后24个月内移植者总生存更优(P=.049),11月龄前出现神经系统症状与总生存降低相关(P=.027)。

要点

  • 46例患者中位移植年龄26月,移植时88%存在神经系统异常。
  • 初次表现后24月内移植者总生存更优(P=.049),总体结果满意但早期诊断可进一步改善结局。

核心结论

  • 移植总体结果满意,但更早诊断可能进一步改善结局。
  • 初次表现后24个月内行造血干细胞移植者总生存更优(P=.049)。
  • 11月龄前出现神经系统症状与总生存降低相关(P=.027)。

研究设计与样本

  • 欧洲血液与骨髓移植学会(EBMT)回顾性研究,纳入21个中心的46例嘌呤核苷磷酸化酶缺乏症患者。
  • 分析初次表现的临床征象及造血干细胞移植后结局。
  • 采用CHIMO评分(认知0-3、听力0-3、互动0-4、运动0-4、职业0-3)在末次随访时评估。

主要发现

  • 初次表现中位年龄7.5(1-48)月,表现为感染41%、神经功能障碍39%、两者兼有15%、自身免疫病5%。
  • 移植时中位年龄26(2-192)月,88%患者存在神经系统异常。
  • 高比例(>50%-100%)/低比例(11%-50%)供者嵌合分别为85%/15%,T淋巴细胞减少缓解。
  • CHIMO总评分中位14(6-17),各成分中位评分分别为3(0-3)、3(1-3)、4(1-4)、3(1-4)、2(0-3)。

关键数值与推荐

  • CHIMO评分分级:无损伤17分;轻度15-16分;中度12-14分;重度<12分。
  • 初次表现后24个月内移植者总生存更优(P=.049)。
  • 11月龄前出现神经系统症状与总生存降低相关(P=.027)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purine nucleoside phosphorylase (PNP) deficiency causes inadequate purine metabolite detoxification, which leads to combined immunodeficiency and variable neurologic symptoms. Hematopoietic stem cell transplantation (HSCT) cures the immunodeficiency, but large studies on the long-term outcomes are lacking. In a retrospective study of the European Society for Blood and Marrow Transplantation, we investigated 46 patients with PNP deficiency from 21 centers. We analyzed the presenting clinical signs and outcomes after HSCT. Cognition (0-3), hearing (0-3), interaction (0-4), movement (0-4), and occupation (0-3) (CHIMO) were scored at the last follow-up (FU) visit (no impairment, 17; mild, 15-16; moderate, 12-14; and severe impairment, <12). The median age at initial presentation was 7.5 (1-48) months. The patients presented with infections (41%), neurological dysfunction (39%), both (15%), or autoimmune disease (5%). At the time of HSCT (median age, 26 [2-192] months), neurological abnormalities were observed in 88% of patients. After a median FU of 7.9 (1.0-22.3) years, 40 patients were alive with a 3-year overall survival (OS)/event-free survival (EFS) probabilities of 86% (confidence interval [CI], 77%-97%)/75% (CI, 64%-89%), respectively. High-level (>50%-100%)/low-level donor chimerism (11%-50%) was observed in 85%/15% of patients, respectively, leading to resolution of T lymphopenia. The median overall CHIMO score was 14 (6-17), while the median scores for each component were 3 (0-3), 3 (1-3), 4 (1-4), 3 (1-4), and 2 (0-3), respectively. Patients who underwent HSCT before 24 months after the initial presentation demonstrated superior OS (P = .049). Neurological symptoms that occurred before 11 months of age were associated with reduced OS (P = .027). While the overall results were satisfactory, earlier diagnosis could further improve outcomes.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Herrmann US, Felber M, Worth A, et al. Hematopoietic stem cell transplantation for purine nucleoside phosphorylase deficiency: an EBMT-IEWP retrospective study. Blood. 2026. PMID: 40983033. doi:10.1182/blood.2025029640

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。